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Data presented here refer to 57,885 patients on lipid-lowering
statin therapy from the Dyslipidaemia International Study
(DYSIS) registry. Subjects were divided into 3 discrete subsets:
those at very high-risk, high-risk, and non-high-risk for car-
diovascular events, with assigned low density lipoprotein
cholesterol (LDL-C) targets of 70 mg/dl, 100 mg/dl and 115 mg/
dl, respectively. Overall, the highest proportion of patients
meeting their LDL-C target was seen in the UAE and Kuwait
(49.5%), while the lowest was seen in Germany (14.3%). The
smallest median distance to target was documented in Canada










A.K. Gitt et al. / Data in Brief 9 (2016) 616–620 617Interpretation and discussion of this data can be found in the
manuscript entitled “Low-density lipoprotein cholesterol in a
global cohort of 57,885 statin-treated patients” (Gitt et al.,
2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Speciﬁcations Tableubject area Biology
ore speciﬁc
subject areaDyslipidemia and cardiovascular riskype of data Tables
ow data was
acquiredWorldwide surveyata format Analyzed
xperimental
factorsObservational registryxperimental
featuresComparison of LDL-C target achievement and distance to target in patients on
chronic statin therapy at differing risk of cardiovascular events.ata source
locationInstitut für Herzinfarktforschung, Ludwigshafen, Germanyata accessibility Data are included in this articleD
Value of the data
 These data are gathered from a large, worldwide registry and insights are therefore applicable to
physicians globally.
 As data are stratiﬁed by individual country, target attainment within different national healthcare
systems can be compared and potential improvements made based on the experience of more
successful countries.
 Data can be used as a basis from which to launch further studies investigating optimal treatment
regimes for patients at risk of cardiovascular events, both globally and within individual countries.1. Data
Table 1 displays the proportion of patients attaining risk based target LDL-C values in a global
cohort, overall and divided by country and region of the world. Table 2 displays the median distance
to risk based treatment targets in a global cohort, overall and divided by country and region of
the world.2. Experimental design, materials and methods
The methodology for DYSIS (a cross-sectional, observational, multicenter registry) has been
described elsewhere [1]. Brieﬂy, statin-treated (mono/combination therapy) outpatients were con-
secutively enrolled at multiple centers located in 30 different countries worldwide. The study was
approved by the relevant ethics committees and carried out in agreement with local laws.
Table 1
Proportions of patients attaining their target LDL-C values.
Country (n) Total Very high-riska High-riska Non-high-riska P-value
% (n/N) % (n/N) % (n/N) % (n/N)
Europe/Canada/Israel
Austria (n¼881) 15.9 (123/772) 12.9 (85/657) 20.7 (6/29) 37.2 (32/86) o0.0001
Baltics (n¼1797) 15.9 (282/1779) 10.9 (151/1386) 20.5 (24/117) 38.8 (107/276) o0.0001
Belgium (n¼909) 35.7 (310/868) 21.6 (116/536) 40.5 (34/84) 64.5 (160/248) o0.0001
Canada (n¼2436) 45.6 (1098/2410) 40.7 (787/1933) 50.3 (79/157) 72.5 (232/320) o0.0001
Denmark (n¼933) 37.7 (338/897) 30.2 (196/650) 45.4 (49/108) 66.9 (93/139) o0.0001
France (n¼4192) 20.6 (835/4061) 14.4 (385/2677) 16.6 (50/302) 37.0 (400/1082) o0.0001
Germany (n¼4216) 14.3 (555/3879) 11.2 (371/3300) 18.9 (44/233) 40.5 (140/346) o0.0001
Greece (n¼755) 17.8 (132/741) 9.2 (42/456) 19.1 (9/47) 34.0 (81/238) o0.0001
Ireland (n¼900) 43.5 (376/865) 35.9 (222/618) 58.6 (51/87) 64.4 (103/160) o0.0001
Israel (n¼100) 29.1 (223/766) 20.3 (121/597) 49.0 (24/49) 65.0 (78/120) o0.0001
Italy (n¼766) 30.7 (206/671) 22.7 (95/419) 29.4 (15/51) 47.8 (96/201) o0.0001
The Netherlands (n¼1199) 30.8 (354/1151) 27.4 (279/1019) 34.1 (15/44) 68.2 (60/88) o0.0001
Norway (n¼957) 29.2 (247/847) 18.5 (112/607) 46.2 (48/104) 64.0 (87/136) o0.0001
Portugal (n¼910) 20.4 (144/706) 11.1 (46/415) 25.0 (13/52) 35.6 (85/239) o0.0001
Russia (n¼1585) 17.0 (189/1114) 12.2 (118/967) 30.3 (10/33) 53.5 (61/114) o0.0001
Slovakia (n¼926) 24.5 (226/923) 16.5 (121/733) 37.3 (19/51) 61.9 (86/139) o0.0001
Slovenia (n¼766) 23.6 (178/755) 19.1 (122/640) 25.6 (10/39) 60.5 (46/76) o0.0001
Spain (n¼3664) 16.7 (580/3463) 10.1 (221/2186) 17.9 (48/268) 30.8 (311/1009) o0.0001
Sweden (n¼958) 27.6 (223/807) 21.4 (141/660) 45.3 (34/75) 66.7 (48/72) o0.0001
UK (n¼1315) 40.9 (426/1041) 38.3 (353/922) 50.0 (13/26) 64.5 (60/93) o0.0001
Middle East/Africa
Egypt (n¼1457) 18.8 (260/1384) 13.2 (157/1188) 28.2 (11/39) 58.6 (92/157) o0.0001
Lebanon/Jordan (n¼603) 41.6 (221/531) 33.0 (120/364) 37.1 (13/35) 66.7 (88/132) o0.0001
UAE and Kuwait (n¼299) 49.5 (135/273) 44.9 (105/234) 40.0 (2/5) 82.4 (28/34) o0.001
Saudi Arabia (n¼1263) 32.5 (388/1194) 26.4 (276/1045) 52.9 (9/17) 78.0 (103/132) o0.0001
South Africa (n¼1029) 48.6 (478/984) 39.9 (288/722) 66.7 (60/90) 75.6 (130/172) o0.0001
Asia
China (n¼22,369) 31.4 (7006/22,345) 23.9 (4067/17,022) 46.4 (687/1481) 58.6 (2252/3842) o0.0001
Total (n¼57,885) 28.1 (15,533/55,227) 21.7 (9097/41,953) 38.0 (1377/3623) 52.4 (5059/9651) o0.0001
a Corresponding LDL-C targets for very high-, high- and non-high-risk patients were o70 mg/dl, o100 mg/dl and 115 mg/dl,
respectively.
A.K. Gitt et al. / Data in Brief 9 (2016) 616–620618Inclusion criteria were as follows: 1) provision of written informed consent, 2) availability of a
fasting blood lipid proﬁle taken within 6–12 months of study entry, at which time the participant had
been on statin therapy for a minimum of 3 months 3) aged Z45 years and on statin therapy at time of
inclusion 4) not participating in a clinical trial.
The 2011 ESC/EAS guidelines on treatment of dyslipidemia were used for stratiﬁcation of patients
into risk categories [2]. Patients considered at “very high risk” of cardiovascular events were those
diagnosed with CHD, diabetes, chronic kidney disease, and/or peripheral artery disease, whereas
those with markedly elevated single risk factors such as total cholesterol 4310 mg/dl or severe
hypertension (SBPZ180 and/or DBPZ110 mmHg) were determined to be “high-risk”. All other
patients were determined to be “not high-risk”. LDL-C targets of 70 mg/dl, 100 mg/dl, and 115 mg/dl
were assigned to very high-, high- and non-high-risk patients, respectively, in accordance with 2011
ESC/EAS guidelines.
Serum lipid levels were obtained from the most recent blood test for each patient, and data on
lipid-lowering agents (statin type, dose, and other concomitant lipid-modifying therapies) that were
being taken by the patient at that time were documented. Simvastatin was used as a reference to
calculate the relative potency of other statins for comparison [3]. A central web-based database at the
Institut für Herzinfarktforschung, Ludwigshafen, Germany was used to collect and store the data.
The SAS© statistical package, Version 9.3 (SAS Institute, Cary, North Carolina, USA) was used for
data analysis purposes. Data were processed and presented as percentages (n/N) or medians (IQR), all
of which were based one the number of patients with data for a particular case available. Categorical
Table 2
Median distance to treatment targets.
Country (n) Totala mg/dl (IQR) Very high-riskb mg/dl (IQR) High-riskb mg/dl (IQR) Non-high-riskb mg/dl (IQR) P-value
Europe/Canada/Israel
Austria (n¼881) 33.0 (18.0, 58.0) 33.0 (19.0, 58.0) 31.0 (9.0, 67.0) 25.5 (9.0, 56.0) 0.06
Baltics (n¼1797) 42.1 (20.5, 71.9) 42.5 (21.6, 73.9) 33.0 (12.9, 69.4) 38.1 (15.3, 60.9) o0.05
Belgium (n¼909) 24.3 (11.0, 44.0) 27.5 (14.0, 47.0) 14.5 (7.0, 30.0) 14.0 (5.0, 33.5) o0.0001
Canada (n¼2436) 18.8 (8.5, 34.4) 18.9 (8.5, 34.4) 17.7 (6.3, 33.4) 17.1 (8.4, 31.9) 0.79
Denmark (n¼933) 24.2 (11.2, 42.1) 26.7 (13.9, 42.1) 22.6 (8.3, 46.9) 16.5 (4.9, 28.9) o0.01
France (n¼4192) 35.0 (18.0, 58.0) 38.0 (19.0, 61.0) 36.5 (17.0, 61.0) 28.0 (15.0, 48.0) o0.0001
Germany (n¼4216) 38.0 (20.0, 61.0) 39.0 (22.0, 62.0) 31.0 (14.8, 54.0) 28.1 (15.0, 45.9) o0.0001
Greece (n¼755) 37.0 (20.0, 60.0) 40.0 (22.0, 65.0) 35.0 (21.0, 50.0) 28.0 (15.0, 50.0) o0.01
Ireland (n¼900) 25.5 (11.2, 46.0) 26.7 (12.6, 46.0) 26.8 (14.7, 44.4) 19.6 (8.7, 38.1) 0.13
Israel (n¼100) 21.0 (9.0, 38.0) 21.3 (9.0, 39.0) 23.0 (12.0, 29.0) 13.0 (7.0, 29.0) 0.13
Italy (n¼766) 29.0 (13.0, 53.0) 32.0 (17.0, 55.5) 22.5 (7.0, 61.5) 22.0 (9.0, 37.0) o0.001
The Netherlands (n¼1199) 26.7 (11.6, 42.5) 26.7 (11.2, 42.1) 27.6 (13.7, 46.9) 31.8 (10.1, 39.7) 0.83
Norway (n¼957) 30.5 (15.1, 49.9) 30.5 (18.9, 51.0) 16.0 (4.4, 31.7) 16.5 (4.9, 47.4) o0.0001
Portugal (n¼910) 39.5 (21.0, 60.0) 42.0 (23.0, 65.0) 35.0 (23.0, 56.0) 33.0 (16.0, 54.0) o0.01
Russia (n¼1585) 38.3 (18.9, 63.0) 38.3 (18.9, 65.0) 26.8 (8.3, 66.7) 28.5 (10.3, 42.4) o0.01
Slovakia (n¼926) 37.1 (18.2, 65.3) 38.7 (19.3, 68.4) 35.3 (16.4, 66.7) 18.8 (8.0, 31.9) o0.0001
Slovenia (n¼766) 38.3 (18.9, 69.2) 39.2 (18.9, 69.2) 23.7 (12.1, 54.7) 30.8 (16.5, 47.4) 0.05
Spain (n¼3664) 39.0 (20.0, 64.0) 42.0 (23.0, 69.0) 39.5 (19.5, 61.0) 32.0 (14.0, 54.0) o0.0001
Sweden (n¼958) 26.7 (15.1, 46.0) 26.7 (15.1, 46.0) 27.6 (12.1, 46.9) 12.6 (8.7, 22.3) o0.01
UK (n¼1315) 19.3 (11.2, 36.3) 19.3 (11.2, 35.6) 28.4 (4.4, 40.8) 24.2 (4.9, 51.3) 0.98
Middle East/Africa
Egypt (n¼1457) 40.0 (20.0, 71.0) 42.0 (20.0, 75.0) 38.5 (22.0, 65.0) 29.0 (13.0, 47.0) o0.01
Lebanon/Jordan (n¼603) 30.0 (13.0, 58.0) 30.0 (13.0, 59.5) 25.5 (11.0, 37.0) 27.0 (13.5, 57.5) 0.37
UAE and Kuwait (n¼299) 25.0 (9.0, 41.0) 25.0 (9.0, 42.0) 23.0 (2.0, 88.0) 11.5 (5.0, 24.0) 0.42
Saudi Arabia (n¼1263) 34.0 (15.1, 56.0) 37.0 (17.0, 57.6) 13.5 (7.1, 24.0) 11.0 (6.0, 22.0) o0.0001
South Africa (n¼1029) 30.3 (14.3, 52.6) 30.5 (14.3, 53.7) 25.1 (13.7, 43.1) 34.7 (13.0, 53.2) 0.54
Asia
China (n¼22,369) 33.1 (15.5, 56.8) 34.8 (16.6, 59.5) 24.9 (11.8, 45.8) 24.2 (10.7, 43.5) o0.0001
Total (n¼57,885) 33.0 (15.8, 57.0) 34.4 (17.0, 59.0) 28.0 (12.1, 51.2) 25.8 (12.0, 47.0) o0.0001
a Total refers to the distance from individual treatment targets, irrespective of group.

















A.K. Gitt et al. / Data in Brief 9 (2016) 616–620620variables were compared by Chi-squared tests and continuous variables by Mann–Whitney–Wilcoxon
(two-tailed) or Kruskal–Wallis (three-tailed) tests. In terms of distance from target, a smaller value
was considered to represent greater target achievement, while a larger value represented poorer
target achievement. P-values r0.05 were considered signiﬁcant.Acknowledgements
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